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Introduction: Detrusor sphincter dyssynergia affects 70% to 80% of all spinal cord in-
jury patients, resulting in increased risk of urinary tract infections (UTIs) and potential 
exposure to antimicrobial resistance. In Brazil, local guidelines recommend intermit-
tent catheterization as the best method for bladder emptying, and two catheter types 
are available: the conventional uncoated PVC and the hydrophilic coated catheters.
Objective: To evaluate the cost-effectiveness of two types of catheters for intermittent 
catheterization from the perspective of the Brazilian public healthcare system.
Materials and Methods: A Markov model was used to evaluate cost-effectiveness in 
those with spinal cord injuries. A primary analysis was conducted on all possible ad-
verse events, and a secondary analysis was performed with urinary tract infections as 
the only relevant parameter. The results were presented as cost per life years gained 
(LYG), per quality-adjusted life years (QALY) and per number of urinary tract infections 
(UTIs) avoided.
Results: The base scenario of all adverse events shows a cost-effective result of hydro-
philic coated catheters compared to uncoated PVC catheters at 57,432 BRL (Brazilian 
Reais) per LYG and 122,330 BRL per QALY. The secondary scenario showed that the 
use of hydrophilic coated catheters reduces the total number of UTIs, indicating that 
an additional cost of hydrophilic coated catheters of 31,240 BRL over a lifetime will 
reduce lifetime UTIs by 6%.
Conclusions: Despite the higher unit value, the use of hydrophilic coated catheters is a 
cost-effective treatment from the perspective of the Brazilian public healthcare system.
InTRODuCTIOn
Every single year, almost 10,000 Brazilians 
suffer from a spinal cord injury (SCI) – an injury 
that comes with great cost for the individual as 
well as for the public healthcare system (1, 2). 
As a consequence of the injury, 70% to 80% are 
diagnosed with detrusor sphincter dyssynergia, a 
dysfunction that leads to incomplete bladder emp-
tying (3). National and International guidelines re-
commend bladder emptying with intermittent ca-
theterization (IC) 4-6 times per day (4-6). Among 
the benefits of IC are the preservation of the struc-
ture and function of the upper urinary tract, redu-
ced risk of vesicoureteral reflux, improvement of 
urinary continence and reduction of urinary tract 
infections (UTI). These benefits allow SCI patients 
to be more independent and have a better quality 
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of life (4). Paradoxically, the most prominent con-
sequence of IC is the recurrence of UTIs. In Brazil, 
quinolones are the first line of antibiotics used to 
treat UTIs. This treatment involves a resistance le-
vel above 30% in some regions (7).
 In Brazil, conventional uncoated 
polyvinylchloride (PVC) catheters, which require 
manual application of lubricant to ease and re-
duce friction, are the most frequently used cathe-
ters. Alternative catheters available in Brazil are 
the pre-lubricated hydrophilic coated ones. These 
catheters have a surface coating, which binds with 
water to form an even coating, thereby elimina-
ting the need for manual application. At the same 
time, it most likely poses a lower risk of UTIs and 
hematuria to SCI patients.
 The aim of this study is to evaluate the 
cost-effectiveness of these two different types of 
catheter for IC in a lifetime perspective. The struc-
ture is based on an international published model 
(8) with adaptations to Brazilian costs and the he-
althcare system.
MATERIALs AnD METhODs
Structure of the Model
 A Markov decision model was adjusted to 
Brazilian reality to evaluate the cost-effectiveness 
of hydrophilic coated versus uncoated PVC cathe-
ters used by SCI patients in Brazil. The analysis 
was performed using the Excel® 2013 software to 
simulate, in monthly cycles, IC-related compli-
cations from the first catheterization until dea-
th (lifetime) (Figure-1). For the primary analysis, 
all adverse events were taken into consideration, 
whereas the secondary analysis covered UTI as the 
single adverse event.
 Based on the original study by Clark et 
al., SCI patients suffer from chronic urinary re-
tention (80% males, 20% females, average age 36 
years old) (8).
 A consequence of urinary retention over 
a long period of time is the impairment of renal 
function. To reflect this reality, three renal stages 
were established in relation to its impact on the 
renal function: “No impairment”, “Significant im-
pairment” and “Renal failure”. It is assumed that 
all new IC users will have “No impairment” and 
that it is not possible to recover or regress to a 
previous stage of renal function, but only progres-
sion of stages (Figure-1).
 UTI is the most common complication of 
IC, and the current model consists of four different 
levels of UTIs that the SCI patient can go throu-
gh. This is a modification compared to the original 
model by Clark et al., however it was considered 
relevant to describe the treatment pathways in Bra-
zil. (8) In this study, we defined the following UTI 
levels: “No UTI”, “UTI treated with first line an-
tibiotics”, “UTI resistant to first line antibiotics” 
and “UTIs resistant to second line antibiotics”. 
All new IC users are simulated to have “No UTI”. 
Regardless of impairment of renal function, SCI 
patient remains subject to the same UTI risk and 
treatment (Figure-1).
 Additional adverse events considered as 
consequences of IC were the development of sep-
sis, urethral injury during catheterization and sub-
sequent urethral stricture, and formation of stones 
within the urinary bladder.
Data input
 The development of UTIs was conside-
red the key parameter in the model. A systema-
tic review of the literature was carried out with 
keywords and MeSH that covered Spinal Cord In-
juries, Hydrophilic Coated Catheters, Economics, 
Costs, Cost Analysis, and related terms for both 
English and Spanish languages in the following 
databases: The Cochrance Library, MEDLINE via 
Pubmed, Literatura Latino-americana e do Caribe 
em Ciências da Saúde (LILACS), and Centre for Re-
views and Dissemination (CRD). Further research 
was conducted on the websites of health techno-
logy assessment agencies and related institutions 
and their databases. Digital searches were comple-
mented by manual searches of bibliographic refe-
rences and abstracts of selected publications.
 This search resulted in identifying seven-
ty-seven studies. Of these, only randomized cli-
nical trials, meta-analysis, reviews, observational 
studies and economic evaluations published befo-
re May 2016 were selected. Eighteen studies met 
these inclusion criteria and were submitted for a 
complete review. The PICO (Population/Interven-
tion/Comparison/Outcome) criteria were used for 
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Figure 1 – Markov decision model – three renal stages and four urinary tract infection (uTI) levels regardless the impairment 
of renal function.
the structured question. Finally, four studies 
evaluating hydrophilic coated and uncoated 
PVC catheters met the criteria and were used for 
the cost-effectiveness study. The baseline risk 
of UTI was based on data from De Ridder et al. 
(2005) (9), Cardenas et al. (2009) (10), Cardenas 
et al. (2011) (11), and Sarica et al. (2010) (12). 
Individual data from each study were compiled 
to calculate the UTI incidence of both catheters. 
The relative risk (RR) of UTI per month between 
hydrophilic and PVC catheters was calculated 
for each one of the four studies mentioned abo-
ve. A weighted average of the relative risks was 
calculated and based on it and the reduction 
risk of UTI was determined. (Table-1).
 The analysis was limited to bladder voi-
ding through intermittent catheterization in 
the SCI population. Other methods for voiding 
dysfunction management, such as indwelling 
catheters or urostomies were not included, as 
they are associated with different risk profi les. 
We focused on IC, once the Brazilian Society 
of Urology recommends this treatment for long-
-term urinary retention patients with neuroge-
nic voiding dysfunction.
 For bacterial resistance, the first line tre-
atment was based on ciprofloxacin. The resis-
tance rate of 34% was determined by D’Addazio 
et al. (7). As second-line antibiotic, acetyl ce-
furoxime was adopted as the drug of choice for 
oral use in cases of failure in the first-line of 
antimicrobial treatment with a resistance level 
of 3.4% (13). A third-line antibiotic treatment 
was defined as ceftriaxone, through parenteral 
administration. The studies evaluated antibac-
terial resistance to community-acquired UTIs. 
For bacterial resistance rate to antibiotics, it 
was decided to use data outside of hospital set-
tings only.
 All other complications included in the 
model can be found in Table-2. For these com-
plications, the keywords and MeSH used in the 
literature search were the same previously des-
cribed for the same database. Due to a limited 
number of studies regarding these other com-
plications and their relation to different types 
of catheter, we decided to include observational 
studies, which resulted in three additional pu-
blications as listed on Table-2 (14-16).
 Within the adopted model, a state of 
quality of life that follows each adverse event 
(utility) was included. We decided to use the ori-
ginal data from The National Institute of Heal-
th and Care Excellence (NICE), since there is no 
data available for the Brazilian population (17). 
For mortality rates, the 2014 Brazilian morta-
lity board of Instituto Brasileiro de Geografi a 
e Estatística (IBGE) (18) was used. The adjust-
ment factors were based on Clark et al. (8) and 
D’Addazio et al. (7).
No renal impairment
UTI resistant to second
line antibiotic
UTI resistant to fi rst
line antibiotic
UTI treated with fi rst
line antibiotic
Renal failure
No UTI
Signifi cant renal
impairment
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Cost Data
 Costs related to UTI treatments, as well as 
the necessary materials for catheterization, were 
obtained from the Banco Nacional de Preços (19), 
except for the hydrophilic coated catheters, which 
were provided by a company in Brazil, conside-
ring the lowest individual price among catheters 
registered and approved by ANVISA (Brazilian 
Health Regulatory Agency). The consultation of a 
single local source (Banco Nacional de Preços) re-
garding the costs related to urinary tract infection 
was determined by the fact of being the aim of the 
current study to evaluate the cost-effectiveness of 
hydrophilic catheters from the perspective of the 
public healthcare system in Brazil. Banco Nacio-
nal de Preços is the sole official source used by the 
Brazilian government for budget calculation. The 
use of foreign countries’ cost data could interfere 
with the analysis and results presented here.
Costs due to lubrication, required when 
using uncoated PVC catheters, were considered 
as reusable lubricant, since this is the most com-
mon practice in Brazil, whilst the unit value of 
each lubricant package was divided by the ave-
Table 1 - urinary tract infection responding to initial antibiotic treatment.
Source Catheter type Patients 
(N)
UTI 
Incidence
Mean Follow-
up months
UTIs per 
month
Weighted 
average 1
Relative Risk
(RR): Hydrophilic 
coated vs PVC
uTI rates in the uncoated PvC catheter population
Cardenas et al. (2011) a Conventional 
PVC
114 - 3-6 0.48 54.49 -
Sarica et al. (2010) b Conventional 
PVC
21 4.00 1.5 2.67 56.00 -
Cardenas et al. (2009) c Conventional 
PVC
23 1.65 12 0.14 3.16 -
De Ridder et al. (2005) d Conventional 
PVC
61 - 12 0.38 23.18 -
Total 219
uTI rates in the hydrophilic coated catheter population
Cardenas et al. (2011) a Hydrophilic 
coated
105 - 3-6 0.48 50.30 1.00
Sarica et al. (2010) b Hydrophilic 
coated
21 1.00 1.5 0.67 14.00 0.25
Cardenas et al. (2009) c Hydrophilic 
coated
22 0.77 12 0.06 1.41 0.47
De Ridder et al. (2005) d Hydrophilic 
coated
61 - 12 0.34 20.74 0.89
Total 209
hydrophilic-coated versus conventional uncoated PvC catheter treatment effect 0.84 (16% 
reduction) 2
1 - number of patients x UTI per month
2 - mean relative risk weighted by the number of patients in each study – (RR a X N a) + (RR b X N b) + (RR c X N c) + (RR d X N d) / (N a + N b + N c + N d)
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Table 2 - Key input parameters.
Parameters Value Source/assumption
Monthly adverse event rates (conventional PvC)
Urinary tract infections 62.48% De Rider et al. (2005), Cardenas et al. (2009)
Cardenas et al. (2011), Sarica et al. (2010)
Bladder stones 0.12% Perrouin-Verbe et al. (1995),
Chai et al. (1995)
Kidney stones 0.12% Assumed same bladder stones
Urethral injury 0.19% Perrouin-Verbe et al. (1995),
Chai et al. (1995)
Urosepsis 0.32% Perrouin-Verbe et al. (1995),
Chai et al. (1995), Weld et al. (2000)
Treatment effect (hydrophilic coated vs PvC) 
Urinary tract infections 0.84 Table 1
Bladder stones 0.90 Clark et al. (2016)
Kidney stones 0.90 Clark et al. (2016)
Urethral injury 0.90 Clark et al. (2016)
Urosepsis 0.90 Clark et al. (2016)
Costs
Monthly cost, PVC catheter* R$ 74.27 Banco de Preços em Saúde (19)
Monthly cost, hydrophilic coated catheter* R$ 608.27 Market Price
Monthly cost, lubricant* R$ 132.75 Banco de Preços em Saúde (19)
Urinary tract infections, per event R$ 554.16 SIGTAP/ TABNET (20, 21)
Urinary tract infections, antibiotics** R$ 60.50 Banco de Preços em Saúde (19)
Urosepsis R$ 708.36 SIGTAP/ TABNET (20, 21)
Urethral injury R$ 605.33 SIGTAP/ TABNET (20, 21)
Kidney stones R$ 524.30 SIGTAP/ TABNET (20, 21)
Bladder stones R$ 721.95 SIGTAP/ TABNET (20, 21)
Major renal impairment, per month R$ 82.60 SIGTAP/ TABNET (20, 21)
Renal failure, per month R$ 2,589.02 SIGTAP/ TABNET (20, 21)
utility decrements
Urinary tract infection 0.060 NICE Model (17) 
Urinary tract infection, resistant 0.104 NICE Model (17) 
Kidney stones 0.050 Clark et al. (2015)
Bladder stones 0.050 Clark et al. (2015)
Urethral injury 0.104 NICE Model (17)
Urosepsis 0.160 NICE Model (17)
Major renal impairment 0.155 NICE Model (17)
Renal failure 0.250 NICE Model (17)
Mortality multipliers
Urinary tract infection 0.000 Model structure
Urinary tract infection, resistant*** 145.270 Clark et al. (2015)
Urinary tract infection, weighted**** 49.390 Calculated based on Schito et al. (2009) (13) 
Urosepsis 797.600 Clark et al. (2015)
Major renal impairment 18.000 Clark et al. (2015)
Renal failure 54.000 Clark et al. (2015)
* Assuming the practice of four catheterizations per day for bladder emptying and the use of half a tube of lubricant per catheterization (2 tubes per day)
** Antibiotic therapy – 1st line (ciprofloxacin 500 mg every 12h for 7 days, oral use; resistance rate = 34%); Antibiotic therapy – 2nd line (cefuroxime 500 mg every 12h for 7 days, oral use; 
resistance rate = 3.4%) and Antibiotic therapy – 3rd line (ceftriaxone 1 g every 12h for 7 days, parenteral).  /    *** Resistance rate to ciprofloxacin = 34%.    /    **** s 145.27*34%* + 0.00*66%
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rage volume used in each procedure, for a mean 
of four catheterizations per day. As indicated by 
the manufacturer, the volume to be inserted into 
the urethra before each catheterization is estima-
ted at 15 grams for men and 3 to 5 grams for 
women. In order to apply the relative proportion 
between sexes in the present study, it was esti-
mated the use of two tubes a day for a total of 
four catheterizations.
 The costs related to procedures, diagnos-
tic exams and treatment of adverse events were 
obtained from the SIGTAP table (20). The hos-
pitalization costs were obtained from TABNET 
data (21). Both SIGTAP and TABNET correspond 
to the official sites for consultation adopted by 
the Brazilian government in the public health-
care system. For calculation purposes, patients 
who reach the hospitalization stage cost the 
public healthcare system approximately 525.60 
BRL (Brazilian Reais) per UTI, and progression to 
sepsis costs 708.36 BRL. The list of all costs and 
sources are presented in Table-2.
Output
 Direct medical costs, life years gained 
(LYG), quality adjusted life years (QALY) and the 
number of UTIs avoided were calculated from 
the perspective of the Brazilian public healthcare 
system. An annual discount of 5% was applied 
to costs, QALY and LYG, but UTIs were not dis-
counted. All results are reported as incremental 
cost-effectiveness ratio (ICER). A deterministic 
one-way sensitivity analysis of parameters was 
performed to assess the robustness of the varia-
bles in the model. Three parameters were consi-
dered key to results and deterministic analysis: 
amount of lubricant, resistance rates to antibio-
tics and UTI rates.
 No official threshold for ICER exists for 
the Brazilian population. In the UK, this figure is 
in the range of £20,000–£30,000 per QALY, and 
in the United States the threshold is US$50,000. 
In Brazil, the ICER threshold was estimated by 
Prado as 147,000 BRL and this was the ICER 
threshold adopted for the evaluation of results in 
this cost-effectiveness study (22).
REsuLTs
 Based on the studies from De Ridder et al. 
(2005) (9), Cardenas et al. (2009) (10), Cardenas 
et al. (2011) (11), and Sarica et al. (2010) (12), the 
monthly risk of developing UTI while using unco-
ated PVC catheters was estimated in 62%, with a 
reduction by 16% while using hydrophilic coated 
catheters (Table-1).
 Within a base case primary analysis, the 
model predicts that with an additional cost of 
31,221 BRL per SCI patient within a life perspec-
tive, an IC user can live an additional 0.54 years 
with the use of hydrophilic coated catheters. In a 
Brazilian setting, the hydrophilic coated catheter is 
considered cost-effective at a level of 122,330 BRL 
per QALY for the base scenario (Table-3).
 For the secondary analysis, considering 
only UTI as an adverse event related to IC, the ICER 
values of 57,468 BRL per LYG and 122,406 BRL 
per QALY were also considered cost effective in 
the Brazilian setting (Table-4). For the secondary 
analysis with UTI as the only parameter, the results 
indicate the need for an investment of approxima-
tely 9,778 BRL per avoided UTI. Additionally, the 
Table 3 - Cost-effectiveness results of primary analysis (all adverse events).
Cost (BRL) QALYs LYG UTI
Conventional PVC 17,255 2.550 5.689 54.73
Hydrophilic coated 48,476 2.805 6.233 51.53
Incremental values 31,221 0.255 0.544 -3.20
ICER (BRL/QALY gained) 122,330 BRL per QALY
ICER (BRL/LYG) 57,432 BRL per LYG
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user will have a 6% reduction of UTIs requiring 
treatment and an increase in QALY by 0.25 within 
a life perspective.
 Three parameters were identified relevant 
to investigate in a deterministic one-way sensiti-
vity analysis (deterministic analysis): the lubrica-
tion, the bacteria resistance level and the UTI rate. 
ANVISA recommends that lubricants for uncoated 
catheters are single-use (23). Therefore, a one-way 
sensitivity analysis increases the number to four 
lubricants per day. By implementing the ANVISA 
recommendation, the incremental cost was reduced 
significantly to R$ 86,831 per QALY. Implementing 
a conservative resistance rate for ciprofloxacin of 
16.5% (24), results were still considered cost-effec-
tive at R$ 122,527 per QALY. For UTI varying rates, 
it was decided to include results from a literature 
review carried out by Li et al. (25), and one sce-
nario based on the study that has been conducted 
over a period of 10+ years on IC users by Cardenas 
et al. (10). Adopting different UTI rates, the levels 
implemented in the base scenario are highly cost-
-effective from 40,188 BRL to 76,796 BRL (Table-5).
DIsCussIOn
 The most frequent complication of inter-
mittent catheterization is urinary tract infection. 
A 12-year follow-up study showed that chronic 
or recurrent UTIs are as frequent as 42% in pa-
tients with IC (26). Throughout the last two de-
cades, the increasing rates of bacterial resistance 
to antibiotics have worried the scientific commu-
nity, and efforts have been made to reduce UTI 
rates. De Ridder et al. prospectively evaluated men 
with neurogenic bladder dysfunction due to spinal 
cord injury, and observed two times fewer symp-
tomatic infections among those using hydrophilic 
catheters (9). Cardenas et al. demonstrated that 
patients with spinal cord injury using hydrophi-
lic catheters required less antibiotic treatment for 
UTIs when compared to those using PVC catheters 
(10). In a randomized study, also with spinal cord 
injury patients monitored from the beginning of 
the rehabilitation phase, a 21% reduction rate was 
observed in the risk of UTI development in the 
initial rehabilitation phase and a delay in the oc-
currence of the first symptomatic UTI event (11). 
Forty percent of spinal cord injury patients with 
intermittent catheterization with hydrophilic ca-
theters monitored over five to nine years still pas-
sed sterile urine (27). In a systematic review with 
five studies involving 462 patients, the incidence 
of symptomatic UTI and hematuria were signi-
ficantly lower in the hydrophilic catheter group 
than in the non-hydrophilic catheter group (25).
 This study was designed to determine the 
cost-effectiveness of two different catheters used 
for patients with spinal cord injury in an intermit-
tent catheterization program. It can provide local 
IC decision-makers with a tool that captures the 
relevant costs, consequences and benefits of two 
different types of catheters in a lifetime perspecti-
ve. The model structure was based on a European 
model published in 2016, specially adapted to the 
Brazilian cost and public healthcare system (8). 
Despite no official cost-effectiveness threshold in 
Brazil, Prado et al. demonstrated that a threshold 
of up to 147,000 BRL is sufficient to consider cost-
-effectiveness in Brazil (22).
Table 4 - Cost effectiveness results of secondary analysis (uTIs).
Cost (BRL) QALYs LYG UTI
Conventional PVC 17,255 2.550 5.689 54.73
Hydrophilic coated 48,495 2.805 6.233 51.53
Incremental values 31,240 0.255 0.544 -3.20
ICER (BRL/QALY gained) 122,406 BRL per QALY
ICER (BRL/LYG) 57,468 BRL per LYG
ICER (BRL/UTI avoided) 9,778 BRL saved per UTI avoided
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Table 5 - Deterministic univariate sensitivity analysis.
Parameters Value tested ICER (BRL/QALY) Source
Deterministic results 122,330 -
Lubricant tube per day
Base case 2 - Table 2
Alternative
4 86,831 ANVISA guideline
1 140,079 Assumed
Resistance level for antibiotics
Base case
34% - D’Addazio et al. (2015), 
Table 2
Alternative
16% 122,527 Kiffer et al. (2011)
45% 122,206 Assumption
uTI reduction*
Base case 16% - Table 1
Alternative
26% 76,796 Li et al. (2013)
53% 40,188 Community data, Cardenas et 
al. (2009)
*The studies come with different UTI rates based on published information
 Considering the above-mentioned 
threshold, after analyzing all possible adverse 
events of IC (primary analysis), as well as when 
UTI was the sole parameter considered (secon-
dary analysis), the use of a hydrophilic coated 
catheter resulted in a highly cost-effective re-
sult. The deterministic sensitivity analysis reve-
aled that despite the amount of lubricant used, 
the bacteria resistance rate to antibiotics and 
different UTI reduction rates, the cost-effecti-
veness favored hydrophilic coated catheters for 
the Brazilian scenario.
 The results match those from the original 
model from Europe (8), as well as a later Japanese 
version (28), where hydrophilic coated catheters 
were proved to be cost-effective despite their hi-
gher unit price. A key difference to the original 
model by Clark et al. (8) was the implementation 
of different treatment pathways in case of bacte-
rial resistance, as well as a higher resistance level 
particularly to ciprofloxacin, the most common-
ly used antibiotic for treating UTIs in Brazil. It is 
well-known that the values of bacteria assumed in 
the current study were those based on community 
general population, and not specifically in patients 
with neurogenic bladder dysfunction. This is rele-
vant, considering that a recent study conducted 
in the United States documented that SCI patients 
have higher rates of antibacterial resistance than 
those observed in the general population (29). The 
adopted model did not consider the important as-
pect of higher antibacterial resistance levels in re-
lation to hospitals or rehabilitation centers.
It is worth noting that the inputs were 
conservative, as the model assumes that all SCI 
patients enter the model without any compli-
cations except the need for IC. SCI patients are 
usually very complex due to several comorbidi-
ties. However, to ensure the model is as objec-
tive as possible and for the purpose of simpli-
fication, it was decided to conduct the analysis 
on less complex SCI patients.
 Although the practice of reusing uncoated 
PVC catheters in Brazil is common, according 
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to the ANVISA, as well as included on the 
manufacturer’s label, the catheters are not 
intended for anything more than single use. 
A recent study involving Paralympic athletes, 
including Brazilians, showed that those with 
re-used catheters presented more than twice the 
UTI rates compared to athletes from European 
countries, where hydrophilic coated catheters 
are the standard of care (5, 30).
 According to scientific evidence, the 
hydrophilic-coated catheters have a lower fric-
tion force, as well as lower rates of hematuria 
when compared to uncoated PVC catheters (31). 
However, these differences were not incorpora-
ted into the model. It is believed that performing 
at least four to six catheterizations per day with 
uncoated catheters is likely to raise the like-
lihood of urethral trauma.
 It has been documented that lack of pre-
ference for a specific catheter can reduce com-
pliance and thereby increase the occurrence of 
catheter-related complications. Hydrophilic-coa-
ted catheters have been associated with greater 
patient satisfaction in aspects such as comfort 
and convenience when compared to uncoated 
PVC catheters (30-32). These parameters were 
not applicable in the structure of the current 
model due a lack of information regarding this 
subjective aspect in our country.
 Regarding uncoated PVC catheters, most 
of them contain softeners such as phthalates that 
may put the users at risk. Although the exposure 
to phthalates risk on the part of neither patients 
nor healthcare professionals was incorporated 
into this model, numerous investigations have 
demonstrated that with continuous exposure to 
phthalates, they will accumulate in the human 
body and therefore affect the hormones – espe-
cially in women and children (33).
COnCLusIOns
 Despite a difference in unit cost of the 
two different types of catheters, the hydrophilic-
-coated catheters seem to be cost-effective wi-
thin a lifetime perspective for SCI patients. The 
results have not considered patient, urologist 
or other healthcare professional preference and 
convenience. An analysis such as a multi-crite-
ria decision analysis would give better insight 
into the preferences of patients and healthcare 
professionals.
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